Skip to contentP
Perspective Therapeutics, Inc.
P
CATXPerspective Therapeutics, Inc. Q1 2018 · 10-Q
Revenue$1.21M$1.21M+12.0% vs Q1 2017 Net Income-$1.55M-$1.55MN/M vs Q1 2017 EPS Diluted-$0.03-$0.03N/M vs Q1 2017 Gross Profit$265,000+452.1% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Perspective Therapeutics, Inc. · CIK 728387 · Engraved from SEC EDGAR
Operating Cash Flow-$1,661,000N/M Free Cash Flowderived-$1,715,000N/M Margins · derivedGross margin21.9%+17.4 pt vs Q1 2017
Operating margin-128.2%+17.5 pt vs Q1 2017
Net margin-127.7%+10.9 pt vs Q1 2017
ended Sep 30, 2017 · filed Nov 14, 2017 · 45 d after period end